| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966561 | Vaccine | 2013 | 7 Pages |
Abstract
⺠A postmarketing study evaluated the safety of LAIV in children 24-59 months of age. ⺠28,226 LAIV recipients were matched with TIV-vaccinated and unvaccinated children. ⺠There was no suggestion of a clinically significant safety signal with LAIV.
Keywords
Postmarketing safetySOBSbiLAIVWTITIVSAERSVKaiser PermanenteURIAGIRADemergency departmentMAEReactive airway diseaseFollow-upshortness of breathRelative riskUpper respiratory tract infectionSerious adverse eventhazard ratioARTinfluenza vaccinelive attenuated influenza vaccineRespiratory syncytial virusChildren
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Seth L. Toback, Christopher S. Ambrose, Abigail Eaton, John Hansen, Laurie Aukes, Ned Lewis, Xionghua Wu, Roger Baxter,